Recursion Pharmaceuticals (RXRX) Accumulated Expenses (2020 - 2026)

Recursion Pharmaceuticals' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $54.2 million for Q1 2026.

• Quarterly Accumulated Expenses fell 4.58% year-over-year to $54.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.2 million (down 4.58% YoY) and the FY2025 annual result came in at $70.2 million, down 14.22% from the prior year.
• Accumulated Expenses was $54.2 million for Q1 2026 at Recursion Pharmaceuticals, down from $70.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $81.9 million in Q4 2024 and bottomed at $23.1 million in Q1 2022.
• A 5-year average of $43.1 million and a median of $39.8 million in 2023 frame the typical range for Accumulated Expenses.
• Peak annual rise in Accumulated Expenses reached 117.89% in 2025, while the deepest fall reached 14.22% in 2025.
• Recursion Pharmaceuticals' Accumulated Expenses stood at $32.9 million in 2022, then jumped by 41.73% to $46.6 million in 2023, then surged by 75.56% to $81.9 million in 2024, then fell by 14.22% to $70.2 million in 2025, then slipped by 22.82% to $54.2 million in 2026.
• Business Quant data shows RXRX's Accumulated Expenses at $54.2 million in Q1 2026, $70.2 million in Q4 2025, and $53.1 million in Q3 2025.